Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
BackgroundThe cardiotoxic effects of doxorubicin, trastuzumab, and other anticancer agents are well known, but molecular genetic testing is lacking for the early identification of patients at risk for therapy-related cardiac toxicity.MethodsUsing the Agena Bioscience MassARRAY system, we genotyped T...
Main Authors: | Pooja P. Advani, Kathryn J. Ruddy, Joerg Herrmann, Jordan C. Ray, Emily C. Craver, Greg Yothers, Reena S. Cecchini, Corey Lipchik, Huichen Feng, Priya Rastogi, Eleftherios P. Mamounas, Sandra M. Swain, Charles E. Geyer, Norman Wolmark, Soonmyung Paik, Katherine L. Pogue-Geile, Gerardo Colon-Otero, Edith A. Perez, Nadine Norton |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1139347/full |
Similar Items
-
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
by: Patricia A. Ganz, et al.
Published: (2021-05-01) -
Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30
by: N. Lynn Henry, et al.
Published: (2022-11-01) -
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
by: Samuel A. Jacobs, et al.
Published: (2019-12-01) -
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
by: Samuel A. Jacobs, et al.
Published: (2020-01-01) -
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
by: Sibylle Loibl, et al.
Published: (2022-09-01)